T2-high asthma

This study follows 335 adults with severe eosinophilic asthma who are taking benralizumab. Researchers want to see if the drug helps patients achieve partial or complete clinical remission—meaning fewer symptoms, no need for steroid pills, and better lung function—over 12 to 24 m…

This study follows 300 adults with severe eosinophilic asthma who are prescribed benralizumab as part of their normal care in Germany. Researchers will track changes in asthma control, lung function, and medication use over one year. The goal is to see how the drug performs outsi…

This study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…

This study tests whether depemokimab, an injected biologic drug, can reduce severe asthma attacks and help patients achieve remission when added to standard care. About 456 adults and adolescents with type 2 asthma at risk of flare-ups will receive either depemokimab or a placebo…

This study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…

This study tests a drug called depemokimab in 150 adults with severe asthma caused by a specific type of inflammation. The goal is to see if the drug can reduce mucus plugs and airway thickening in the lungs. Participants will receive the drug and have lung scans and breathing te…

This phase 3 trial is testing whether adding benralizumab (an injectable drug) to medium-dose inhalers can reduce asthma attacks in people with eosinophilic asthma whose symptoms are not well controlled. About 400 participants aged 12 to 75 will be randomly assigned to receive be…

This Phase 3 trial tests a new drug called 610 in 480 Chinese adults with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. Participants receive either 610 or a placebo injection for 52 weeks. The main goal is to see if 610 reduces t…

This phase 2 study tests a new drug called SHR-1703, given as multiple injections under the skin, for people with eosinophilic asthma. The goal is to see if it is safe and helps control asthma over the long term. About 200 adults will take part, and researchers will monitor side …

This study looks at a protein called TSLP, which is involved in airway inflammation, and its two forms (short and long) in people with different types of asthma. Researchers will measure TSLP levels in blood and nasal cells from 70 adults with asthma and compare them to healthy c…

This study follows 1,000 people aged 12 and older in China who have severe eosinophilic asthma and are prescribed benralizumab. Researchers will track how well the drug controls asthma symptoms over time using questionnaires, and note reasons for stopping or switching treatment. …

This study is for adults with asthma whose symptoms don't improve with standard inhalers. Researchers will use advanced MRI and CT scans to see if structural problems in the airways—like narrowing or mucus plugs—prevent inhaled medications from reaching the lungs. Participants wi…